Journal article

rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461

Jinbae Son, Katherine M Hannan, Gretchen Poortinga, Nadine Hein, Donald P Cameron, Austen RD Ganley, Karen E Sheppard, Richard B Pearson, Ross D Hannan, Elaine Sanij

Frontiers in Cell and Developmental Biology | FRONTIERS MEDIA SA | Published : 2020

Abstract

Hyperactivation of RNA polymerase I (Pol I) transcription of ribosomal RNA (rRNA) genes (rDNA) is a key determinant of growth and proliferation and a consistent feature of cancer cells. We have demonstrated that inhibition of rDNA transcription by the Pol I transcription inhibitor CX-5461 selectively kills tumor cells in vivo. Moreover, the first-in human trial of CX-5461 has demonstrated CX-5461 is well-tolerated in patients and has single-agent anti-tumor activity in hematologic malignancies. However, the mechanisms underlying tumor cell sensitivity to CX-5461 remain unclear. Understanding these mechanisms is crucial for the development of predictive biomarkers of response that can be util..

View full abstract